Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Vitoria

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2021
World Health Organization Guidance to Support Human Immunodeficiency Virus Care Models During the Coronavirus Disease 2019 EraNathan Ford, Marco Vitoria, Meg Doherty
Current Opinion in HIV and AIDS|November 29, 2012
Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challengesMarco Vitoria, Stefano Vella, Nathan Ford
Journal of the International AIDS Society|February 14, 2018
Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat AllNathan Ford, Marco Vitoria, Meg Doherty
Tropical Medicine & International Health : TM & IH|July 3, 2016
Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapyGreer Waldrop, Meg Doherty, Marco Vitoria, et al.
Current Opinion in HIV and AIDS|December 19, 2018
Current and future priorities for the development of optimal HIV drugsMarco Vitoria, Ajay Rangaraj, Nathan Ford, et al.
Journal of the International AIDS Society|December 10, 2013
Getting to zero HIV deaths: progress, challenges and ways forwardNathan Ford, Marco Vitoria, Gottfried Hirnschall, et al.
The Lancet. Infectious Diseases|August 2, 2016
Tenofovir resistance and first-line antiretroviral therapyNathan Ford, Marco Vitoria, Meg Doherty, et al.
Antiviral Therapy|October 14, 2014
Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settingsMarco Vitoria, Nathan Ford, Meg Doherty, et al.
Current Opinion in HIV and AIDS|April 14, 2017
Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?Nathan Ford, Marco Vitoria, Meg Doherty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2014
Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohortsNathan Ford, Andrew Hill, Marco Vitoria, et al.
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 24, 2021
World Health Organization Guidance to Support Human Immunodeficiency Virus Care Models During the Coronavirus Disease 2019 EraNathan Ford, Marco Vitoria, Meg Doherty
Current Opinion in HIV and AIDS|November 29, 2012
Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challengesMarco Vitoria, Stefano Vella, Nathan Ford
Journal of the International AIDS Society|February 14, 2018
Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat AllNathan Ford, Marco Vitoria, Meg Doherty
Tropical Medicine & International Health : TM & IH|July 3, 2016
Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapyGreer Waldrop, Meg Doherty, Marco Vitoria, et al.
Current Opinion in HIV and AIDS|December 19, 2018
Current and future priorities for the development of optimal HIV drugsMarco Vitoria, Ajay Rangaraj, Nathan Ford, et al.
Journal of the International AIDS Society|December 10, 2013
Getting to zero HIV deaths: progress, challenges and ways forwardNathan Ford, Marco Vitoria, Gottfried Hirnschall, et al.
The Lancet. Infectious Diseases|August 2, 2016
Tenofovir resistance and first-line antiretroviral therapyNathan Ford, Marco Vitoria, Meg Doherty, et al.
Antiviral Therapy|October 14, 2014
Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settingsMarco Vitoria, Nathan Ford, Meg Doherty, et al.
Current Opinion in HIV and AIDS|April 14, 2017
Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?Nathan Ford, Marco Vitoria, Meg Doherty, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2014
Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohortsNathan Ford, Andrew Hill, Marco Vitoria, et al.
Pageof 10